Resultados da busca - Jaume Capdevila

Refinar Resultados
  1. 1
    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

    Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib por Jaume Capdevila, Neda Stjepanovic

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  2. 2
    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours

    GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours por Teresa Alonso‐Gordoa, Jaume Capdevila, Enrique Grande

    Publicado em 2014
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  3. 3
    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

    Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies por Enrique Grande, Juan J. Díez, Carles Zafón, Jaume Capdevila

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer

    Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer por Anubha Gupta, Barbara Jarząb, Jaume Capdevila, Robert Shumaker, Ziad Hussein

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    What is the status of immunotherapy in thyroid neoplasms?

    What is the status of immunotherapy in thyroid neoplasms? por Alejandro García‐Álvarez, Jorge Hernando, Ana Carmona-Alonso, Jaume Capdevila

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  6. 6
    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era

    Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era por Jaume Capdevila, Ahmad Awada, Dagmar Führer‐Sakel, Sophie Leboulleux, Patrick Pauwels

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  7. 7
    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia

    Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia por Rodrigo A. Toledo, Camilo Jiménez, Gustavo Armaiz-Peña, Carlota Arenillas, Jaume Capdevila, Patricia L. M. Dahia

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Cabozantinib for the treatment of solid tumors: a systematic review

    Cabozantinib for the treatment of solid tumors: a systematic review por Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodríguez‐Antona, Lidia Martín, Daniel Castellano

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  9. 9
    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials

    Genomics Review of Selective <scp>RET</scp> Inhibitors Sensitivity in Thyroid Cancer Clinical Trials por Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Alejandro García‐Álvarez, Ginesa García‐Rostán, Jaume Capdevila, Jorge Hernando

    Publicado em 2025
    Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  10. 10
    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors

    Streptozotocin, 1982–2022: Forty Years from the FDA’s Approval to Treat Pancreatic Neuroendocrine Tumors por Jaume Capdevila, Michel Ducreux, Rocio García‐Carbonero, Enrique Grande, Þorvarður R. Hálfdánarson, Anne Couvelard, Salvatore Tafuto, Staffan Welin, Vicente Valentí, Ramón Salazar

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  11. 11
    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

    Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies por Enrique Grande, Michael C. Kreißl, Sébastiano Filetti, Kate Newbold, Walter Reinisch, Caroline Robert, Martin Schlumberger, Lærke Kjær Tolstrup, José Luís Zamorano, Jaume Capdevila

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  12. 12
    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

    Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in dev... por Rocio García‐Carbonero, Roberto García‐Figueiras, Alberto Carmona‐Bayonas, Isabel Sevilla, Àlex Teulé, María Quindós, Enrique Grande, Jaume Capdevila, Javier Aller, Javier Arbizu, Paula Jiménez‐Fonseca

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Revisão
    Salvar na lista
    Na minha lista:
  13. 13
    Sorafenib in metastatic thyroid cancer

    Sorafenib in metastatic thyroid cancer por Jaume Capdevila, L. Iglesias, Irene Halperín, Ángel Segura, Javier Martínez‐Trufero, María Ángeles Vaz Salgado, J. Corral, Gabriel Obiols, Enrique Grande, Juan J. Grau, Josep Tabernero

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors por Catherine Lombard‐Bohas, James C. Yao, Timothy J. Hobday, Eric Van Cutsem, Edward M. Wolin, Ashok Panneerselvam, Sotirios Stergiopoulos, Manisha H. Shah, Jaume Capdevila, Rodney F. Pommier

    Publicado em 2014
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

    Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results por Marianne Pavel, Jarosław B. Ćwikła, Catherine Lombard‐Bohas, Ivan Borbath, Tahir Shah, Ulrich F. Pape, Jaume Capdevila, Francesco Panzuto, Xuan-Mai Truong Thanh, Aude Houchard, Philippe Ruszniewski

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

    Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer por Bruce Robinson, Martin Schlumberger, Lori J. Wirth, Corina E. Dutcus, James Song, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Jaume Capdevila, Steven I. Sherman, Makoto Tahara

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer

    Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve <i>RET</i> -Mutant Medullary Thyroid Cancer por Lori J. Wirth, Marcia S. Brose, Rossella Elisei, Jaume Capdevila, Ana O. Hoff, Mimi I. Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Xia Meng, Patricia Maeda, Eric J. Sherman

    Publicado em 2022
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors

    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors por Massimo Falconi, Barbro Eriksson, Gregory Kaltsas, Detlef K. Bartsch, Jaume Capdevila, Martyn Caplin, Beata Kos‐Kudła, Dik J. Kwekkeboom, Guido Rindi, Günter Klöppel, Nicholas S. Reed, Réza Kianmanesh, Robert T. Jensen

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

    Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer por Garazi Serna, Fiorella Ruíz‐Pace, Jorge Hernando, Lidia Alonso, Roberta Fasani, Stefania Landolfi, Raquel Comas, José Jiménez, Elena Élez, Susan Bullman, Josep Tabernero, Jaume Capdevila, Rodrigo Dienstmann, Paolo Nucíforo

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

    A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors por Josep Tabernero, Luc Dirix, Patrick Schöffski, Andrés Cervantes, José A. López-Martín, Jaume Capdevila, Ludy van Beijsterveldt, Suso Platero, Brett M. Hall, Zhilong Yuan, R.E. Knoblauch, Sen Hong Zhuang

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: